Haemonetics Corp
NYSE:HAE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
71.16
97.37
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Haemonetics Corp
Earnings Call Analysis
Q1-2025 Analysis
Haemonetics Corp
Haemonetics Corporation kicked off its fiscal year 2025 with a notable first quarter, reporting a total revenue of $336 million. This reflects an 8% growth on a reported basis and 3% on an organic basis, signaling a solid beginning despite underlying challenges in specific business segments. Adjusted earnings per diluted share stood at $1.02, noting a slight decrease of 3% from the robust first quarter of the previous year.
The plasma revenue saw a decline of 3% during the first quarter following a significant growth of 35% in the prior year. Notably, North America’s disposal revenue dropped by 5%, largely due to ongoing planned transitions by key customers. However, excluding these temporary disruptions, U.S. collection volumes demonstrated growth in the high single digits. Looking ahead, the company reaffirmed its guidance for plasma revenue to be in the negative range between 3% to 6% for FY 2025, primarily due to the aforementioned customer transitions.
Blood Center revenue faced a 2% decline; however, apheresis revenue grew by 3% owing to strong demand in various markets. The decline in whole blood revenue by 14% indicates an ongoing rationalization effort aimed at optimizing contributions and enhancing overall margins. Haemonetics maintains its guidance for Blood Center revenue growth at negative 5% to negative 7% for FY 2025.
In contrast, the Hospital segment thrived, posting a remarkable 31% increase in revenue, including contributions from newly integrated sensor-guided technologies. Organic revenue growth in this division reached 13%. Significantly, the company projects reported revenue growth in the Hospital segment of 27% to 32%, and organic growth between 13% to 16% for FY 2025, reflecting confidence in ongoing product acceptance and market penetration.
Despite initial challenges, Haemonetics is actively working to enhance its operational efficiencies. The adjusted gross margin for the quarter was reported at 55.3%, marking an improvement of 110 basis points year-over-year. However, operating expenses increased by 17%, stressing the importance of balancing growth investments with margin maintenance. For the full fiscal year, the adjusted operating margin is projected to be between 23% to 24%, with aspirations to reach high 20s in subsequent years.
The company's financial health remains robust, with a cash position of $344 million at quarter-end. This improvement of $166 million is attributed to strategic debt refinancing and capital deployment aimed at facilitating growth opportunities. Free cash flow expectations remain steady at $130 million to $180 million for FY 2025, which underscores the company’s commitment to financial prudence.
Recent product innovations, including the Express Plus technology, are set to enhance productivity and collection efficiency, potentially boosting revenue growth in the plasma market. The full rollout of new vascular closure technologies, such as the VASCADE MVP XL, is expected to drive market demand and facilitate significant upward growth in the interventional space. Haemonetics appears poised for continued market expansion, leveraging its technological advantages effectively.
While the company acknowledged geopolitical challenges, particularly in China, it remains focused on strengthening its position in North America and Europe. The leadership expressed optimism regarding new account penetration and improved performance through strategic investments and operational excellence. These efforts aim to mitigate current pressures and position the company strategically for future growth.
Overall, Haemonetics exhibits resilience through a diversified portfolio and operational efficiencies while navigating near-term market fluctuations. Investors can expect moderate revenue growth across segments, with enhanced opportunities in the Hospital business and innovations in product offerings. The company’s commitment to maintaining strong financial health, coupled with strategic market adaptations, supports a cautiously optimistic outlook for fiscal year 2025.
You don't have any saved screeners yet
Thank you for standing by, and welcome to Haemonetics Corporation's First Quarter Fiscal Year 2025 Earnings Conference Call. [Operator Instructions].
I would now like to hand the call over to Olga Guyette, Vice President, Investor Relations and Treasury. Please go ahead.
Good morning, everyone. Thank you for joining us for Haemonetics' First Quarter Fiscal Year 2025 Conference Call and Webcast. I'm joined today by Chris Simon, our CEO; and James D'Arecca, our CFO. This morning, we posted our first quarter fiscal year 2025 results to our Investor Relations website, along with our fiscal '25 guidance.
Before we begin, a quick reminder that all revenue growth rates discussed today are organic, unless specified otherwise, and exclude the impact of currency fluctuation and acquisitions. Our organic revenue growth guidance for fiscal year 2025 incorporates 15 weeks of revenue from offsets due to the acquisition closing date being in December 2023.
We'll also refer to other non-GAAP financial measures to help investors understand Haemonetics' ongoing business performance. Please note that these measures exclude certain charges and income items. For a full list of excluded items, reconciliations to our GAAP results and comparisons with the prior year periods, please refer to our first quarter fiscal year 2025 earnings release available on our website.
Our remarks today include forward-looking statements, and our actual results may differ materially from anticipated results. Factors that may cause our results to differ include those referenced in the safe harbor statement in today's earnings release and in our other SEC filings. We do not undertake any obligation to update these forward-looking statements.
And now I'd like to turn it over to Chris.
Thanks, Olga. Good morning, and thank you all for joining. Today, we reported first quarter revenue of $336 million, growth of 8% on a reported basis and 3% organically and adjusted earnings per diluted share of $1.02, a 3% decrease from a strong first quarter in the prior year. The start of our fiscal year reflects the strength and the breadth of our product portfolio, our capacity for continued innovation and growth and the resilience of our business to succeed in dynamic markets as we navigate ongoing geopolitical challenges.
We advanced the delivery of plasmapheresis technologies proven to safely lower the cost to collect, reinforcing our status as the leader in addressing the industry's most critical needs. Our blood center solutions are enabling self-sufficient global plasma supply and helping meet increased demand for platelet therapies.
In Hospital, we are integrating recent acquisitions, launching new products and extending our reach and relevance in attractive markets, while delivering robust growth in the rest of the portfolio. Our results underscore Haemonetics' ability to create significant value for our customers and our shareholders. We remain committed to accelerating revenue growth expanding our margins and enhancing productivity, and we are confident in our strategy for sustained profitable growth.
Turning now to our business unit results. Plasma revenue declined 3% in the first quarter after growing 35% last year. North America disposal revenue was down 5%, driven by CSL's planned transition. Excluding the transition, and an unforeseen temporary customer plasma center outage, U.S. collection volume growth was in the high single digits. North America software and Europe disposable revenue each grew double digits in the quarter.
Strong end market demand for IG replacement therapies and the planned expansion of fractionation capacity across the industry support long-term growth in the plasma collection market. Near term, customers have a heightened focus on lowering cost per liter.
We have completed more than 30 million Persona collections and have compelling real-world evidence of safe and consistent yield enhancements. Full market release of our Express Plus technology is now underway, significantly improving collection time, door-to-door time and center throughput. We plan to upgrade the remainder of our NexSys customers to Express Plus and Persona before the end of this fiscal year.
Our advanced technology is an enabler of profitable growth for us and our customers. We expect to gain additional market share in the U.S. and globally to continue to deliver revenue growth that outpaces the plasma collections market. We reaffirm our plasma revenue growth guidance for FY 2025 in the range of negative 3% to negative 6%, driven by the previously announced customer transition.
Blood Center revenue decreased 2% in the quarter. Apheresis revenue grew 3%, driven by continued demand for plasma across several markets and red cell collection share gains in the U.S., partially offset by order timing among distributors. Whole blood revenue declined 14% as we continue to rationalize the franchise to optimize durable contribution as part of our company-wide margin expansion. The increasing focus on plasma self-sufficiency continues to drive international demand for source plasma. We are strengthening our global customer relationships to expand NexSys' reach. Our FY 2025 guidance for Blood Center revenue growth is unchanged in the range of negative 5% to negative 7%.
Moving to our Hospital business. First quarter revenue grew 31% on a reported basis, including our newly acquired sensor guided technologies and esophageal protection device and 13% organically. Our interventional franchise has been busy. The commercial team completed comprehensive training across our expanded product portfolio, swiftly adapted to evolving market trends and ensured sufficient commercial and clinical support throughout our U.S. account network. We achieved 68% revenue growth on a reported basis and 19% organic growth. With training and integration largely completed, the team is focused on hitting individual product targets and selling the entire interventional technologies portfolio across both electrophysiology and interventional cardiology.
Growth in the quarter was driven by continued penetration of the top 600 U.S. accounts with our vascular closure devices and increased emphasis on utilization across addressable procedures. The limited market release of VASCADE MVP XL, which features a 58% larger collagen plug was a success, with very positive results across procedures and highly encouraging responses from early adopters. This new device allows us to successfully participate in the rapidly growing market of [ Pulsed-field ] ablation and increased adoption in procedures like left atrial appendage disclosures, where we've seen minimal usage with VASCADE MVP. With full market release underway and an ongoing development program to expeditiously expand the label to larger access points, we are further strengthening our leadership in enabling treatment of atrial fibrillation regardless of the ablation technology used.
We are making significant progress internationally as well. having established our presence in over 100 accounts in Japan with further plans and our additional European markets this year. We are strengthening our field force support to convey our unique clinical and economic benefits over the competition, and we expect to sustain 20%-plus growth in the vascular closure business and further expand our leadership position in this $2.7 billion market. Our newly acquired products delivered a total of $18 million in revenue further accelerating growth of this franchise. It's early days, but we feel good about the progress we have made and the business case for these acquisitions is intact.
We are excited to launch SavvyWire in Europe in the coming months and extend the unique benefits of this guidewire to more patients by broadening our market access. We are also highly encouraged by the progress and positive feedback for ensoETM with its considerable clinical benefits, including reduced esophageal injury during radio frequency cardiac ablation. It presents a compelling market opportunity as a reliable, safe and significantly more cost-effective alternative to emerging catheter-based technologies safely and effectively treat atrial fibrillation.
Our Blood Management Technologies franchise also had a strong first quarter with 10% revenue growth. [indiscernible] management delivered double-digit growth in North America, driven by strong capital sales and increased disposable utilization on the TEG 6s platform. Our new Heparin neutralization cartridge is helping clinicians serve fully heparinized patients and enabling deeper penetration into accounts performing adult cardiovascular surgeries and liver transplantation.
Success in the U.S. was partially offset by geopolitical market challenges in China. Transfusion management benefited from new account openings for SafeTrace Tx and BloodTrack in North America and EMEA. We invested in additional channel expansion and further enhance the platform, positioning us to [ win share ]. Cell Salvage also had an impressive quarter across all markets with additional upside from last time buy orders in our older generation device.
We are excited about the opportunities ahead of us and expect growth in our hospital business to accelerate in subsequent quarters, driven by new product launches, sales synergies from newly acquired products and improving efficiency of scale. We reaffirm our previously issued guidance and expect hospital reported revenue growth of 27% to 32% and organic revenue growth of 13% to 16% in FY 2025. We expect a strong year ahead as we continue to refine our portfolio to drive sustainable revenue growth at attractive margins. For the total company, we continue to expect reported revenue growth to be in the range of 5% to 8% and organic growth to be flat to 3% for FY 2025.
Now I'll pass it over to James to discuss the rest of our financial performance and fiscal year 2025 guidance.
Thank you, Chris, and good morning, everyone. As Chris mentioned, this quarter has been an exceptionally productive one across the organization. We successfully launched new products and continued to integrate acquisitions all while maintaining a strong focus on our short and midterm objectives. The effect of portfolio evolution is becoming more meaningful in driving higher margins and positioning us for sustained success. We ended the first quarter with an adjusted gross margin of 55.3%, up 110 basis points from last year, driven by volume and mix with a disproportionate contribution from the growing momentum in our Hospital business unit. Adjusted operating expenses in the first quarter were $114.9 million, an increase of $16 million or 17% compared with the first quarter of the prior year.
As a percentage of revenue, adjusted operating expenses increased by 250 basis points to 34.2%. The increase in adjusted operating expenses in the quarter was primarily due to the recent acquisitions of Opsens and Attune Medical, along with additional growth investments.
First quarter adjusted operating income was $71 million, an increase of $0.8 million or 1% and our adjusted operating margin was 21.1%, down 150 basis points compared with a very strong quarter last year. Nearly half of that decline was related to FX impacts with the remainder due to increased adjusted operating expenses. Sequentially, our adjusted operating margin expanded by 230 basis points compared with the fourth quarter of fiscal '24, primarily driven by improved adjusted gross margin lower performance-based compensation and higher plasma inventory, reducing the need for freight expediting.
This was our first full quarter with both Opsens and Attune, while there is more work to do to synergize these acquisitions fully, we already see benefits of these high-margin products, helping us offset increased costs. We expect these benefits to increase as we expand our commercial strategies in the top U.S. accounts in fiscal '25 and beyond.
We reaffirm our adjusted operating margin guidance for fiscal '25 at 23% to 24%, anticipating steady improvements each subsequent quarter as we progress towards our long-range plan of achieving operating margins in the high 20s. The adjusted income tax rate was 20% for the first quarter compared with 21% one year ago. We expect our fiscal '25 adjusted income tax rate to be approximately 23%. First quarter adjusted net income was $52.4 million, down $1.3 million or 2%, and adjusted earnings per diluted share was $1.02 down 3% when compared with the strong first quarter of fiscal '24. Changes in the adjusted income tax rate, interest expense and foreign exchange had a $0.07 negative impact on the first quarter adjusted earnings per diluted share when compared with the prior year. We remain optimistic about our prospects and our ability to capitalize on emerging market trends, optimize our portfolio mix and realize savings through operational excellence.
We reaffirm our adjusted earnings per diluted share guidance of $4.45 to $4.75. At the midpoint of our guidance range, we now anticipate approximately $0.34 of impacts from interest expense, FX, income tax and share count with interest expense being responsible for about half of that.
Turning now to select cash flow and balance sheet highlights. In our first quarter, we had a cash outflow of $27 million primarily related to lower net income and higher working capital due to increased inventory and the timing of certain payments. Combined with additional CapEx spends, net of proceeds from the sale of one of our manufacturing facilities, we had a free cash outflow of $17 million. Our expectation for free cash flow remains unchanged at $130 million to $180 million in fiscal '25. Cash on hand at the end of the quarter was $344 million, up $166 million since the end of fiscal '24 primarily due to our recently completed debt financing net of the repurchase of a portion of our convertible notes due in 2026.
New [ capped ] call transactions and transaction-related fees and the paydown of borrowings on the revolving credit facility used to help fund the recent acquisitions of Opsens and Attune. Our updated debt capital structure includes a recently refinanced credit facility consisting of a $250 million unsecured Term Loan A and a $750 million unsecured revolving facility as well as $1 billion in convertible notes, which puts our net leverage ratio at approximately 2.8x EBITDA at the end of our first quarter.
In addition to the credit facility refinancing discussed on our May earnings call, during the first quarter, we issued $700 million of convertible securities with a 2.5% coupon and a [ capped ] call ensuring the protection of the conversion price until the share price reaches $180 or a 100% premium over the issue price of $90 a share. This transaction allowed us to mitigate risks associated with upcoming convertible note maturities and prefund a portion of our growth agenda at attractive interest rates while helping to ensure we remain in a strong financial position when pursuing additional growth opportunities.
Before we transition to Q&A, I would like to share some key takeaways as we reflect on the start of our fiscal year and our strategic direction moving forward. Our first quarter performance demonstrated our strength and impact. We continued to expand our industry presence and leadership across our business units while proving our resilience as we advanced our growth amidst changing market trends and geopolitical challenges. We are forwarding our innovation with new products, both launched and in the pipeline. Our focus on innovation is paving the way for further expansion into high-growth markets and enhancing our financial performance, both in the near term and in the long run.
Our debt financing was an important step in strategically enhancing our access to capital and increasing flexibility in capital deployment. This will help us ensure we remain in a strong financial position when pursuing additional organic or inorganic growth opportunities.
And finally, we remain committed to achieving the objectives outlined in our long-range plan. Through our long-term strategic focus, we are cultivating a powerful sustainable growth engine poised to deliver value to our shareholders well into the future.
Thank you, and we can now proceed with Q&A.
[Operator Instructions] Our first question comes from the line of Anthony Petrone of Mizuho Americas.
Maybe start with plasma and one on hospital. On the plasma end of the equation, maybe a little bit, Chris, on where do you think we are in the cycle just coming out of COVID, meaning inventory builds at the [ fractionators ]. Are we approaching some level of supply-demand equilibrium our [ fractionator ] still building inventories? And a follow-up on plasma would be -- we're seeing increasing reports of adverse events with [indiscernible] reported to the [ MAD ] database. Not sure if there's any update on just where CSL is tracking in terms of their wind down? Is it in line with your expectations? Is it slower? Is it faster? And then I'll have one follow-up on hospital.
With regards to plasma supply demand, demand remains really robust, right? We look at short-term and long-term theirs by our estimations, an additional increase in fractionation capacity over the next decade in excess of 6% that's already been announced where there's confirmed commitments. It will grow from there. We presume we feel quite good about the long-term demand for IG-based replacement therapies and our customers' commitment therein.
In the near term, I think it really does vary significantly from one customer to the next. We called out a specific set of issues at one customer's collection centers early in the quarter. And I think some folks took advantage of that to trim back a bit on what has been collecting hand over fist to replenish their inventories.
We do see a shift and a rebalancing towards inventory rebuild combined with lower cost per liter. The benefit for that both in the quarter and over the remainder of the year is a heightened demand for everything and anything we can do to improve productivity, increase demand for both upgrades and conversions you see that in kind of our performance over the course of the year. So we still feel quite good about where we are in the cycle. There is a rebalancing, and that will play forward as you would expect.
With regards to our competitors' device, I'm going to leave that aside for now. What I would say is that in terms of the agreement with CSL, nothing has changed. They're purchasing according to the forecast. We know there's an $85 million floor on that based on the agreement that's in place and really don't have anything further to say about it at this point in the year.
And then a follow-up on hospital [ beyond VASCADE MVP ]. Maybe just a little bit on the attach rate to Pulsed-field ablation. PFA volumes had another good quarter in the June period. And so maybe a little bit on the attach rate of MVP to PFA. And when you look at [ Excel ], what will be the benefit of introducing that into the market? Do you get an increased attach rate to PFA with that new solution?
Pulsed-field ablation is, for sure, a disruptive force in the market. We spent a lot of time modeling this, as you could imagine, both for vascular closure but also for esophageal protection. What's happening is very much consistent with what we forecast would happen. The advent of MVP XL a game changer for us. And there's a lot of speculation in the market as the TAM being reduced, et cetera. We don't see any of that.
Crystal clear, PFA is a net positive for Haemonetics Interventional Technologies portfolio. The new XL product has completed limited market release over 350 procedures across a wide range of different therapeutics products performed exceptionally well. Feedback has been truly outstanding. So get that into the market now, we're going to proceed a bit ahead of schedule with full market release because we think it's the right technology across a range of different applications. And so one of the things quite powerful for us is not only on ablation of all forms, but also left [indiscernible] appendage closure, which is an area where the base MVP product enjoyed a lot of success because it's really just not the right technology. We have a 58% larger collagen plug associated with XL, and we think that's really well positioned for the market going forward.
Our next question comes from the line of Mike Matson of Needham.
Just -- start with plasma. So I think you mentioned that you expect to upgrade the [indiscernible] of our customer's Express Plus and Persona person by the end of the fiscal year. So is it safe to assume that there's still kind of a pricing tailwind there in that part of the business, obviously, excluding [ their ] CSL?
Yes, Mike. Well, we now anticipate that all of our North American customers on NexSys will have upgraded to both Express Plus and Persona on their existing centers. And yes, the product is priced to reflect the technological advantages that are gained from both pieces of that part of the equation.
And then just a couple on the interventional business. So with VASCADE MVP XL, are you getting a price premium for that? And then just in terms of the sales force, the cross-training that occurred is that completed? And to what degree do you think that was disruptive in the quarter that you just reported?
Yes. So the XL product is a 58% larger plug, as I mentioned a moment ago. We do command a modest premium for that. We want to be cost effective. And it's one of the things that we look at same-day discharge, time to ambulation, et cetera. It's an incredibly cost-effective therapy. There is price increase. But relative to the base ablation RF or especially [ now PSA ]. It's a really economical form of closure.
In terms of the training, Mike, you're exactly right. This was a big lift, right? We went from a sales force that was exceptionally good closure across a variety of procedures, and we've now introduced both Guidewire technology, sensor-based guidewire technologies and esophageal protection. It is a classic portfolio sale. And I think if anything, in reflection, I'd say we took our time, we are going slow to go faster further over time. And we want to get this right. If you think about the nature of TAVR procedures, for example, where SavvyWire plays a critical role. It's a much more involved procedure. The role of the representatives, both our territory managers and our clinicals is much more critical and we want to make sure they are fully equipped and confident to be able to provide the support. We think we're there now. It did probably take a little more time in the quarter than we had originally anticipated. But again, going slow to go faster further is the right answer for us here.
Our next question comes from the line of Andrew Cooper of Raymond James.
Maybe first, just on plasma, Thinking back to the commentary last quarter and into the year. You talked about the non-CSL business, I think, growing 8% to 12%. Now you're talking about converting more of those customers to Express Plus and Persona. So just would love an update on that metric and how you think about the remaining customers and the growth as well as maybe a little more color on some of the share gains you seem increasingly confident about.
Yes. So look, we guided at the beginning of the year, we were looking at a combination of underlying collection demand our ability to command a price premium for the new superior technology and share gains. And I think all three of those forces are at work. There's going to be puts and takes amongst them, Andrew, on a quarter-to-quarter basis. We left the guidance unchanged because we are confident, particularly those latter two factors, upgrades and share gains are back-end loaded. And we knew that, and we expect that to build over the course of the year. So we feel confident leaving the guidance as is. There's probably a bit of -- it's our first quarter and as a general practice, I'd prefer we don't change guidance after one quarter. We just built the forecast 90 days ago, and we want to live into it a bit. If there's an opportunity to change it as the year progresses, we will. But for where we sit right now, we feel quite good about both CSL and the non-CSL forecast.
And then maybe just on hospital. You've called out a couple of items that really are going to help with the acceleration from sort of the near the lower end of the guide to start the year. Can you maybe size for us new product contribution versus revenue synergies for some of the efficiencies of the sales force that you talked about to help us think about that. Again, acceleration from the low teens, maybe closer towards the mid-teens in terms of the midpoint of guidance.
Sure, Andrew. Vascular closure is the real engine within the portfolio, particularly in North America and particularly in utilization, given that we are now well north of 80% of account penetration across the [ T 600 ]. So we'll drive utilization, that's critical, that is the biggest single driver. The additional product overlay, we called out, there's an additional $18 million of revenue in the quarter. that's included, and it will be meaningfully accretive to our gross margins as the year progresses. In the quarter, it was actually dilutive to our operating income margins. I'm going to let James comment more on that, but again, this goes slow to go faster further, we didn't act more aggressively on the cost synergies because we're in the process of listening and learning. They're both quite good companies. They're good at what they do, and we wanted to make sure we understood at a more intimate level what they do, what's their secret of success and how do we make sure we incorporate and build upon that. So that's what you see in the quarter. As the year progresses, synergies, both cost synergies and sales synergies will really come into effect, and that's what's reflected in our guidance.
Our next question comes from the line of Larry Solow of CJS Securities.
I guess just a couple of follow-ups on the plasma side. Chris, or James, just give us the volume price, the breakdown in the quarter? I don't know if you -- if that's available, just approximately. And then on the Persona, how much approximately how many have already switched to -- or adopted Persona [indiscernible] of your customers?
Let me start with that, and I'll let James answer the breakdown. In terms of Persona, it's not a big secret, we've had more than 50% of the procedures heading into the year. We're well north of that and moving quickly against the remainder. So we'll provide updates at a more substantive basis when jointly with our customers, everybody is comfortable doing that, Larry, but it's proceeding rapidly, and we feel quite good about it. We want to be cautious because we don't control, right? We've said this from the outset with NexSys. We will move absolutely as fast as our customers are prepared to move, but no faster. And in this case, they now want to move quite quickly, and that's what you see in our results going forward.
And Larry, on the volume price split out, and I'll refer to the non-CSL customers, that's predominately volume. As you heard Chris talking about, we expect technology switches and share gains to be more back-end loaded.
So not much on the price side, mostly volume. And then could you just speak real briefly just on the VASCADE, the MVP XL system, the larger [indiscernible] sort of the market opportunity there [ and in of your rollout plans? ]
Yes. So just to reiterate, we went into limited market release. We want to make sure that we had proper use case really understood the devices performance. We've obviously done extensive animal testing and have a very good level of comfort, but we wanted to do the limited market release, make sure that it's performing as expected. As I said, feedback has been absolutely outstanding, now north of 350 procedures across a number of very high-performing centers. Feedback has been extraordinary, right, as good as anything we've seen or heard. So the device performs as advertised. It will get broad spectrum use as appropriate. And where we don't yet have indications on our label for certain appendices hole sizes, we are actively pursuing that with the regulatory authorities, and we expect that to be forthcoming. So but the device is intact, performing well. We're now compiling real-world evidence, and we'll do that even more extensively when we go into full release now to be able to get a broader label expansion.
Our next question comes from the line of Joanne Wuensch of Citi.
I want to just spend a minute more on vascular closure please. I'm under the impression that there's still a large percentage of procedures that are manual compression procedures. Could you sort of quantify what's using our closure device at this stage and what moves people towards manual compression. And then I also want to go back to the PSA opportunity. I think that a little bit of clarification of why you think VASCADE XL could be better for PSA would be really great.
Yes, our biggest competition in vascular closure worldwide is some combination of compression and suturing figure typically. And so we are looking -- we've penetrated, as I said, more than 80% of the [ T 600 ] that does 90% of the procedures in the U.S. within those, our utilization rates are still in the low to mid-40s. And that's our biggest single opportunity is converting folks off of manual compression or suturing to our more sophisticated clearly superior technology. And so that's a process that's underway.
When we say we've penetrated an account, we may have one set of clinicians or one EP lab within that account using our closure device. We still have to work our way through the others. In some cases, there are challenges with value-added committees, what's their cycle for meeting? Do we have the approval, can -- clinicians aware that they're able to use the technology. And then what we do see with VASCADE in all forms is that once a clinician has adopted. It's incredibly sticky. It's just a better procedure, and you see that in all the use cases in terms of the outcomes, in terms of patient satisfaction, we hear that, the nursing staff hears that. And then after the fact when they start to accumulate some volume, they can see how beneficial it is to the economics of the hospital overall. So it really checks all boxes and it's better clinically, it's better economically and we have an increasing body of evidence, real-world evidence to support that case. So we feel quite good about it.
With regard to PFA, we've done extensive animal testing before we brought MVP to the market for regulatory approval. We got the PFA. As I mentioned before in our last call, and we wanted to proceed with a limited market release, just to make sure we have first-hand experience on the use case before we do what we're doing now, which is roll out broadly. Does that answer your question?
It's close enough. Thank you very much.
Our next question comes from the line of Michael Petusky of Barrington Research.
Chris, I think last quarter, you had talked about some progress for vascular closure in Japan in terms of active accounts and also sort of talked about, hey, Europe has been a little bit slower in terms of penetrating and you talked about vagaries around reimbursement from country to country and some differences in treatment methodologies. I'm just wondering, any learnings in any of those markets that would be interesting to share?
So VASCADE in Japan is an unmitigated success. We were able to secure not only the market release from the regulatory authorities, but very favorable reimbursement. And you see that Japan has always been a safety-first medical device market and VASCADE is an incredibly safe product. The data they have there in markets has been really helpful. So we're in excess of 100 accounts now. We work through a third-party distributor. That just continues to go from strength to strength. We're really, really delivering in the Japanese market. And I think there's additional upside for us as the year progresses there.
Europe is a more mixed story. The reimbursement has been a challenge. There are some vagaries with the reimbursement that same-day discharge doesn't have the same reimbursement benefits that it would have in the U.S. So we're working our way through that, changing it where appropriate. And there's a hybrid model of organic sales team, but some joint work with distributors. So very confident in the profile. I'm very confident in the long-term success. We are converting from a market that does primarily suturing as opposed to compression and therefore, some of the discussion around the economic benefits and time to discharge, et cetera, is more nuanced. We have a lot of confidence that we'll be successful. It's just going to be a slower build, which is what we're experiencing.
And James, I may have missed this or you may have not mentioned it. Did you talk about any impact from operational excellence in the quarter, by any chance?
In the quarter, I believe the amount for the full year was $9 million in total with $5 million drop through, and we didn't break out anything separate from the quarter.
Thank you. I would now like to turn the conference back to Chris Simon for closing remarks. Sir?
Again, thank you all for your time this morning. I hope what you take away from our results is the resilience and the diversification of our portfolio, particularly across our three value drivers. If I start with NexSys, there's clearly a rebalancing amongst our customers in terms of cost per liter in addition to having ample inventory supply, it really favors our value proposition, and we're seeing that in terms of accelerated upgrades, and we anticipate additional share gains as the year progresses.
[ TEG ] continues to hum along. There are geopolitical challenges, particularly in China, and we saw some headwinds there that we are working our way through, they're unlikely to get resolved in the short term. We will continue to work at it. And fortunately, we have really outsized strength in both North America and EMEA, much larger markets and a really highly energized team that's fully committed to delivering against that.
And then Interventional Technologies, as I called out earlier, PFA is a disruptive and very positive influence in the market. but it is also a net positive for us, particularly now with the launch of MVP XL. And we've largely completed the integration and the training that was all part of the original plan. And I think you'll see that team really find its footing and move forward with a much more sophisticated portfolio sale that is part of the long-term plan that we had delivered.
So across our three big value drivers, we're coming into our own. I'm excited about what we were able to do even when each of those faced external challenges in the quarter with the rest of the portfolio. And I think as those three come back online as expected, we just go from strength to strength. So thanks for the time this morning. I appreciate the questions.
This concludes today's conference call. Thank you for participating. You may now disconnect.